

Docket No. UCIVN-003C

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1- 34 (Canceled)

Claim 35 (Original) A method for preparing an implantable device for a sustained delivery of a substance within a body of a human or an animal subject, said method comprising the steps of:

- (A) dissolving a biocompatible polymer in a suitable solvent solution to produce a polymer-solvent solution;
- (B) adding said substance to said polymer-solvent solution to produce a polymer-solvent solution-substance admixture;
- (C) drying said polymer-solvent solution-substance admixture to form a substantially dry mass;
- (D) adding a liquid to said mass to cause said mass to soften and;
- (E) manipulating said softened mass to a desired shape.

Claim 36 (Original) A method according to Claim 35 which further comprises a step F, said step F comprising refrigerating said mass.

Claim 37 (Original) A method according to claim 35 wherein a second polymer-solvent solution-substance admixture made by steps (A) and (B) is added to said substantially dry mass of said step (C) and said second polymer-solvent solution-substance admixture is allowed to dry.

Claim 38 (Original) A method according to claim 35 wherein said polymer is non-biodegradable.

Claim 39 (Original) A method according to claim 38 wherein said non-biodegradable polymer is selected from the group consisting of Hydron, polyester, polycarbonate, polysulfone, polyvinyl chloride, polyethylene, polypropylene, poly(N-vinyl pyrrolidone),

Docket No. UCIVN-003C

poly(methyl methacrylate), poly(vinyl alcohol), poly(acrylic acid), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), mixtures thereof and combinations thereof.

Claim 40 (Original) A method according to claim 38 wherein said non-biodegradable, polymer is Hydron.

Claim 41 (Original) A method according to claim 35 wherein said polymer is biodegradable.

Claim 42 (Original) A method according to claim 41 wherein said, biodegradable polymer is selected from the group consisting of poly (ethylene glycol), polyvinylpyrrolidone, polylactides (PLA), polyglycolides (PGA), poly(lactide-co-glycolides) (PLGA), polyanhydrides, polyorthoesters, mixtures thereof and combinations thereof.

Claim 43 (Original) A method according to claim 35 wherein said solvent solution comprises an organic solvent.

Claim 44 (Original) A method according to claim 35 wherein said solvent solution comprises ethanol.

Claim 45 (Original) A method according to claim 35 wherein said solvent solution comprises about 70 to about 95% ethanol.

Claim 46 (Original) A method according to claim 35 wherein said substance is a chemical.

Claim 47 (Original) A method according to claim 35 wherein said substance is a therapeutic agent.

Docket No. UCIVN-003C

Claim 48 (Original) A method according to claim 35 wherein said substance is a biomolecule.

Claim 49 (Original) A method according to claim 35 wherein said substance is a therapeutic biomolecule.

Claim 50 (Original) A method according to claim 35 wherein said substance is a protein.

Claim 51 (Original) A method according to claim 35 wherein said substance is a steroid.

Claim 52 (Original) A method according to claim 35 wherein said substance is a hormone.

Claim 53 (Original) A method according to claim 35 wherein said substance is an RNA, DNA or combination thereof.

Claim 54 (Original) A method according to claim 35 wherein said substance is an anti-sense oligoribonucleotide sequence, antisense oligonucleotide sequence or a combination thereof.

Claim 55 (Original) A method according to claim 35 wherein said substance is an anti-sense oligonucleotide, anti-sense oligoribonucleotide or combination thereof to a focal adhesion kinase RNA.

Claim 56 (Original) A method according to claim 35 wherein said substance is an anti-sense oligonucleotide anti-sense oligoribonucleotide or combination thereof to a focal adhesion kinase gene.

Claim 57 (Original) A method according to claim 35 wherein said substance comprises VEGF, bFGF or a combination thereof.

Docket No. UCIVN-003C

Claim 58 (Original) A method for using an implantable device comprising a step of introducing a device produced according to claim 35 into a body of a human or animal subject such that said substance will be released from said device.

Claim 59 (Original) A method according to claim 58 wherein said introducing step comprises a step of implanting said device into an eye.

Claim 60 (Original) A method according to claim 58 wherein said introducing step comprises a step of implanting into a vitreous of an eye by surgical means.

Claim 61 (Original) A method according to claim 58 wherein said introducing step comprises a step of implanting said device into a subchoroidal space, where a sclera is cut to expose a choroidea.

Claim 62 (Original) A device according to claim 58 wherein said substance causes a therapeutic benefit to occur in said body of said subject into which said device is implanted.

Claim 63 (Original) A method according to claim 58 wherein said introducing step causes a desired disease or disorder in said animal so as to provide an animal model for said disease or disorder.

Claim 64 (Original) A method according to claim 63 wherein said disorder is neovascularization.

Claim 65 (Original) A method according to claim 63 wherein said disease is age-related macular degeneration.

Claim 66 (Original) An implantable substance delivery device for a sustained delivery of a substance within a body of a human or an animal subject made by method according to claim 35.

Docket No. UCIVN-003C

Claim 67 (Original) A method for preparing an implantable device for a sustained delivery of a substance within a body of a human or an animal subject, said method comprising the steps of:

- (A) dissolving a biocompatible polymer in a suitable solvent solution to produce a polymer-solvent solution;
- (B) adding said substance to said polymer-solvent solution to produce a polymer-solvent solution-substance admixture;
- (C) drying said polymer-solvent solution-substance admixture
- (D) adding a second polymer-solvent solution-substance admixture to said air-dried polymer-solvent solution-substance admixture of said step (C) and said second polymer-solvent solution-substance admixture is allowed to dry;

wherein said biocompatible polymer is selected from the group consisting of biodegradable polymers and non-biodegradable polymers.

Claim 68 (Original) A method according to claim 67 comprising a step after D, wherein said step comprises:

- adding a liquid to said mass to cause said mass to soften;
- manipulating said softened mass to a desired shape.

Claim 69 (Original) A method according to claim 67 comprising a step after D wherein said step comprises refrigerating said mass.

Claim 70 (Cancelled)

Claim 71 (Currently Amended) A method according to claim ~~70~~ 67 wherein said non-biodegradable polymer is selected from the group consisting of Hydron, polyester, polycarbonate, polysulfone, polyvinyl chloride, polyethylene, polypropylene, poly(N-vinyl pyrrolidone), poly(methyl methacrylate), poly(vinyl alcohol), poly(acrylic acid),

Docket No. UCIVN-003C

polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), mixtures thereof and combinations thereof.

Claim 72 (Original) A method according to claim 70 wherein said non-biodegradable, polymer is Hydron.

Claim 73 (Cancelled)

Claim 74 (Currently Amended) A method according to claim ~~73~~ 67 wherein said , biodegradable polymer is selected from the group consisting of poly (ethylene glycol), polyvinylpyrrolidone, polylactides (PLA), polyglycolides (PGA), poly(lactide-co-glycolides) (PLGA), polyanhydrides, polyorthoesters, mixtures thereof and combinations thereof.

Claim 75 (Original) A method according to claim 67 wherein said solvent solution comprises an organic solvent.

Claim 76 (Original) A method according to claim 67 wherein said solvent solution comprises ethanol.

Claim 77 (Original) A method according to claim 67 wherein said solvent solution comprises about 70% ethanol.

Claim 78 (Original) A method according to claim 67 wherein said substance is a chemical.

Claim 79 (Original) A method according to claim 67 wherein said substance is a therapeutic agent.

Claim 80 (Original) A method according to claim 67 wherein said substance is a biomolecule.

Docket No. UCIVN-003C

Claim 81 (Original) A method according to claim 67 wherein said substance is a therapeutic biomolecule.

Claim 82 (Original) A method according to claim 67 wherein said substance is a protein.

Claim 83 (Original) A method according to claim 67 wherein said substance is a steroid.

Claim 84 (Original) A method according to claim 67 wherein said substance is a hormone.

Claim 85 (Original) A method according to claim 67 wherein said substance is an RNA, DNA or combination thereof.

Claim 86 (Original) A method according to claim 67 wherein said substance is an anti-sense oligoribonucleotide sequence, antisense oligonucleotide sequence or a combination thereof.

Claim 87 (Original) A method according to claim 67 wherein said substance is an anti-sense oligonucleotide, anti-sense oligoribonucleotide or combination thereof to a focal adhesion kinase RNA.

Claim 88 (Original) A method according to claim 67 wherein said substance is an anti-sense oligonucleotide anti-sense oligoribonucleotide or combination thereof to a focal adhesion kinase gene.

Claim 89 (Original) A method according to claim 67 wherein said substance comprises VEGF, bFGF or a combination thereof.

Claim 90 (Original) A method for using an implantable device comprising a step of introducing a device produced according to claim 67 into a body of a human or animal subject such that said substance will be released from said device.

Docket No. UCIVN-003C

Claim 91 (Original) A method according to claim 90 wherein said introducing step comprises a step of implanting said device into an eye.

Claim 92 (Original) A method according to claim 90 wherein said introducing step comprises a step of implanting into a vitreous of an eye by surgical means.

Claim 93 (Original) A method according to claim 90 wherein said introducing step comprises a step of implanting said device into a subchoroidal space, where a sclera is cut to expose a choroidea.

Claim 94 (Previously Amended) A method according to claim 90 wherein said substance causes a therapeutic benefit to occur in said body of said subject into which said device is implanted.

Claim 95 (Original) A method according to claim 90 wherein said introducing step causes a desired disease or disorder in said animal so as to provide an animal model for said disease or disorder.

Claim 96 (Original) A method according to claim 95 wherein said disorder is neovascularization.

Claim 97 (Original) A method according to claim 95 wherein said disease is age-related macular degeneration.

Claim 98 (Original) An implantable substance delivery device for a sustained delivery of a substance within a body of a human or an animal subject made by method according to claim 67.